Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
General19 hours agoSearch underway for missing boat off South Australia’s Cape Jaffa
-
Noosa News19 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys
-
General21 hours agoReuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism
-
Noosa News21 hours agoChristmas tragedy: NSW woman dies after alleged deliberate hit-and-run on Sunshine Coast